Prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa and association with clinical outcomes in patients: an observational study
Open Access
- 16 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (3) , 793-798
Abstract
To describe the prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa (CRPA) and evaluate the association with clinical outcomes. Colistin heteroresistance was evaluated in CRPA isolates collected from patients without cystic fibrosis in Atlanta, Georgia, USA using two definitions: HR1, growth at 4 and 8 mg/L of colistin at a frequency ≥1 × 10−6 the main population; and HR2, growth at a colistin concentration ≥8× the MIC of the main population at a frequency ≥1 × 10−7. A modified population analysis profile (mPAP) technique was compared with reference PAP for detecting heteroresistance. For adults hospitalized at the time of or within 1 week of CRPA culture, multivariable logistic regression estimated the association between heteroresistance and 90 day mortality. Of 143 colistin-susceptible CRPA isolates, 8 (6%) met the HR1 definition and 37 (26%) met the HR2 definition. Compared with the reference PAP, mPAP had a sensitivity and specificity of 50% and 100% for HR1 and 32% and 99% for HR2. Of 82 hospitalized patients, 45 (56%) were male and the median age was 63 years (IQR 49–73). Heteroresistance was not associated with 90 day mortality using HR1 (0% in heteroresistant versus 22% in non-heteroresistant group; P = 0.6) or HR2 (12% in heteroresistant versus 24% in non-heteroresistant group; P = 0.4; adjusted OR 0.8; 95% CI 0.2–3.4). Colistin heteroresistance was identified in up to 26% of patients with CRPA in our sample, although the prevalence varied depending on the definition. We did not observe an apparent association between colistin heteroresistance and 90 day mortality.Keywords
Funding Information
- Centers for Disease Control and Prevention Emerging Infection Program (U50CK000485)
- National Institute of Allergy and Infectious Diseases at the National Institutes of Health (UM1AI10468)
- Antibacterial Resistance Leadership Group fellowship (AI141883 to J.H.A. and AI148661 to D.S.W.)
- National Institute of Allergy and Infectious Diseases at the National Institutes of Health (1U19AI158080-01)
- Emory University’s Investigational Clinical Microbiology Core
This publication has 21 references indexed in Scilit:
- Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonateInternational Journal of Antimicrobial Agents, 2016
- The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort StudyClinical Infectious Diseases, 2016
- Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacaeNature Microbiology, 2016
- Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosaScientific Reports, 2016
- Antimicrobial Heteroresistance: an Emerging Field in Need of ClarityClinical Microbiology Reviews, 2015
- Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysisAntimicrobial Resistance & Infection Control, 2014
- Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosaJournal of Medical Microbiology, 2013
- Association Between Colistin Dose and Microbiologic Outcomes in Patients With Multidrug-Resistant Gram-Negative BacteremiaClinical Infectious Diseases, 2012
- Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple InoculaAntimicrobial Agents and Chemotherapy, 2011
- Minimal Size of Coffee Ring StructureThe Journal of Physical Chemistry B, 2010